tm logo
GFCAS12
Live/Registered
REGISTERED

on 11 May 2021

Last Applicant/ Owned by

1F, 38, Nakseongdae-ro, Gwanak-gu

Seoul

KR

08790

Serial Number

88862249 filed on 07th Apr 2020

Registration Number

6344786 registered on 11th May 2021

in the Principal Register

Correspondent Address

Jun-Hwa Jeong

Jun-Hwa Jeong

2650 Park Tower Drive, Suite 800

Vienna, VA 22180

Filing Basis

No Filing Basis

Disclaimer

NO DATA

GFCAS12

Veterinary diagnostic reagents for use in veterinary genetic testing; Diagnostic preparations for veterinary purposes; Enzymes for medical purposes for genome editing-based therapy; Genome editing-based treatment preparations in the nature of preparations for detecting mutation in genes for medical purposes; Protein arrays for medical diagnostic purposes; Biological preparations for the treatment Read More

Classification Information


Class [005]
Pharmaceutical Products


Veterinary diagnostic reagents for use in veterinary genetic testing; Diagnostic preparations for veterinary purposes; Enzymes for medical purposes for genome editing-based therapy; Genome editing-based treatment preparations in the nature of preparations for detecting mutation in genes for medical purposes; Protein arrays for medical diagnostic purposes; Biological preparations for the treatment of cancers, rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, psoriasis, diabetes, multiple sclerosis, heart attack, systemic lupus erythematous, age-related macular degeneration, diabetic retinopathy, prevention of pneumonia, anemia, chronic migraine, hepatitis B, hemophilia, respiratory syncytial virus (RSV) prophylaxis, HPV prevention, varicella virus vaccine, growth hormone deficiency, osteoporosis, allergic asthma, chronic idiopathic urticaria, infertility, prevention of meningococcal disease, cystic fibrosis, paroxysmal nocturnal hemoglobinuria, autoimmune diseases infectious diseases for medical or veterinary purposes; Cultures of microorganisms for medical purposes; Cells for medical purposes; Reagents for use in medical genetic testing; Stem cells for medical purposes; Diagnostic preparations for medical purposes; Medicinal protein in the nature of protein arrays for medical diagnostic purposes; Medicinal enzymes; Medicines for human purposes and medicines for animals in the nature of medicines for cancers, rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, psoriasis, diabetes, multiple sclerosis, heart attack, systemic lupus erythematous, age-related macular degeneration, diabetic retinopathy, prevention of pneumonia, anemia, chronic migraine, hepatitis B, hemophilia, respiratory syncytial virus (RSV) prophylaxis, HPV prevention, varicella virus vaccine, growth hormone deficiency, osteoporosis, allergic asthma, chronic idiopathic urticaria, infertility, prevention of meningococcal disease, cystic fibrosis, paroxysmal nocturnal hemoglobinuria, autoimmune diseases, infectious diseases; Surgical implants grown from stem cells in the nature of surgical implants comprised of living tissue; Pharmaceutical preparations for genome editing-based therapy of rare inherited disorders; Ferments for medical or veterinary use; Preparations for detecting mutation in genes for medical purposes; Nucleic acid sequences for medical and veterinary purposes; Enzymes for medical purposes

Mark Details


Serial Number

No 88862249

Mark Type

No Service/Collective Mark

Attorney Docket Number

No KBI-176TM

44D Filed

No

44D Current

No

44E filed

No

44E Current

No

66A Filed

No

66A Current

No

Current Basis

No

No Basis

No

Legal History


Show more

Status DateAction Taken
11th May 2021REGISTERED-PRINCIPAL REGISTER
23rd Feb 2021PUBLISHED FOR OPPOSITION
23rd Feb 2021OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
03rd Feb 2021NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
16th Jan 2021APPROVED FOR PUB - PRINCIPAL REGISTER
29th Dec 2020TEAS/EMAIL CORRESPONDENCE ENTERED
28th Dec 2020CORRESPONDENCE RECEIVED IN LAW OFFICE
28th Dec 2020TEAS RESPONSE TO OFFICE ACTION RECEIVED
02th Jul 2020NOTIFICATION OF NON-FINAL ACTION E-MAILED
02th Jul 2020NON-FINAL ACTION WRITTEN